The Indian market has gained 1.7% recently and is up 41% over the last 12 months, with earnings expected to grow by 17% per annum over the next few years. In this thriving environment, identifying stocks with strong fundamentals and growth potential can offer significant opportunities for investors.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Bharat Rasayan | 8.15% | 0.10% | -7.93% | ★★★★★★ |
| Pearl Global Industries | 72.24% | 19.89% | 41.91% | ★★★★★☆ |
| Indo Amines | 82.32% | 17.15% | 19.98% | ★★★★★☆ |
| S J Logistics (India) | 11.71% | 90.19% | 60.29% | ★★★★★☆ |
| Lotus Chocolate | 13.51% | 28.10% | -6.06% | ★★★★★☆ |
| KP Green Engineering | 13.73% | 47.44% | 61.28% | ★★★★★☆ |
| Monarch Networth Capital | 32.66% | 31.02% | 50.24% | ★★★★☆☆ |
| Sanstar | 50.30% | -8.41% | 48.59% | ★★★★☆☆ |
| Basilic Fly Studio | 1.96% | 55.35% | 81.67% | ★★★★☆☆ |
| Rir Power Electronics | 54.23% | 16.42% | 34.78% | ★★★★☆☆ |
Let's explore several standout options from the results in the screener.
LT Foods (NSEI:LTFOODS)
Simply Wall St Value Rating: ★★★★★★
Overview: LT Foods Limited engages in the milling, processing, and marketing of branded and non-branded basmati rice and rice food products in India, with a market cap of ₹151.02 billion.
Operations: The company generates revenue primarily from the manufacture and storage of rice, amounting to ₹81.21 billion.
LT Foods, a notable player in the rice market, has demonstrated impressive financial health with a net debt to equity ratio of 25.3%, which is satisfactory. The company’s earnings grew by 35.7% over the past year, outpacing the food industry’s growth rate of 16.7%. Trading at a price-to-earnings ratio of 24.7x, it offers good value compared to peers and the Indian market average (34.4x). Additionally, LT Foods reported Q1 FY2025 sales of INR 20.71 billion and net income of INR 1.55 billion, reflecting robust performance despite recent regulatory challenges and fines potentially impacting operations minimally (up to INR100k).
- Click to explore a detailed breakdown of our findings in LT Foods' health report.
Explore historical data to track LT Foods' performance over time in our Past section.
Marksans Pharma (NSEI:MARKSANS)
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research, manufacturing, marketing, and sale of pharmaceutical formulations across various international markets including the United States, North America, Europe, the United Kingdom, Australia, and New Zealand; it has a market cap of ₹132.32 billion.
Operations: Marksans Pharma generates its revenue primarily from the sale of pharmaceutical formulations, amounting to ₹22.68 billion. The company's operations span multiple international markets including the United States, North America, Europe, the United Kingdom, Australia, and New Zealand.
Marksans Pharma, a small cap player in the pharmaceuticals sector, has shown impressive growth with earnings rising 21.7% over the past year. The company's debt to equity ratio improved from 19.9% to 11.7% in five years, indicating prudent financial management. Trading at a P/E ratio of 39.9x, it remains below the industry average of 42.8x, suggesting good relative value. Recently, Marksans received a positive inspection report from USFDA and is exploring M&A opportunities to expand into Europe.
Nila Spaces (NSEI:NILASPACES)
Simply Wall St Value Rating: ★★★★★☆
Overview: Nila Spaces Limited is involved in real estate development activities and has a market cap of ₹104.71 billion.
Operations: The company generates revenue primarily through real estate development activities. With a market cap of ₹104.71 billion, it focuses on residential and commercial projects.
Nila Spaces, a small cap real estate firm, has shown promising financial health with its debt to equity ratio plummeting from 64.4% to 0.9% over five years. The company recently turned profitable, reporting INR 25.57 million in net income for Q1 2024 against a previous year’s loss of INR 2.49 million. Its P/E ratio of 26.7x is attractive compared to the Indian market's average of 34.4x, and it also boasts positive free cash flow at INR 423 million as of September 2023.
- Navigate through the intricacies of Nila Spaces with our comprehensive health report here.
Review our historical performance report to gain insights into Nila Spaces''s past performance.
Make It Happen
- Unlock more gems! Our Indian Undiscovered Gems With Strong Fundamentals screener has unearthed 487 more companies for you to explore.Click here to unveil our expertly curated list of 490 Indian Undiscovered Gems With Strong Fundamentals.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:MARKSANS
Marksans Pharma
Engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally.
Flawless balance sheet with reasonable growth potential.
